Antiviral Combination Therapies Market 2027 By, Type, Indication, Route of Administration, Distribution Channel | The Insight Partners

Antiviral Combination Therapies Market Forecast to 2027 - COVID-19 Impact and Global Analysis By ( NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, Others ); Type ( Branded, Generic ); Indication ( HIV, Hepatitis, Others ); Route of Administration ( Oral, Intravenous ); Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Others )

Report Code: TIPRE00015971 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

When combination of three or more than three drugs are used to treat viral disease, it is known as antiviral combination therapy. For instance, combination of drugs is used to treat HIV. Combination of drugs helps in preventing the virus from replicating in the body. This helps in reducing the damage on patient's immune system.

MARKET DYNAMICS

The antiviral combination therapies market is driving due to the growing prevalence of viral disease, increase in research and development activities to develop new drugs and technological advancement in pharmaceutical and biopharmaceutical industry. However, availability of vaccines for viral infections may restrict the growth of the global Antiviral combination therapies market.

MARKET SCOPE

The "Antiviral Combination Therapies Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of antiviral combination therapies market with detailed market segmentation by drug combination, type, indication, route of administration, and distribution channel. The antiviral combination therapies market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in antiviral combination therapies market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The antiviral combination therapies market is segmented on the basis of drug combination, type, indication, route of administration, and distribution channel. Based on drug combination, the market is segmented as NRTI/NNRTI, integrase inhibitor/NRTI, NRTI, NRTI/protease inhibitor, and others. The type segment is divided into branded, and generic. The indication segment is segmented into HIV, hepatitis, and others. The route of administration segment is segmented into oral, and intravenous. The distribution channel segment is segmented into hospital pharmacies, retail pharmacies, others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Antiviral combination therapies Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Antiviral combination therapies market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Antiviral combination therapies market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Antiviral combination therapies Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Antiviral combination therapies market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Antiviral combination therapies market are anticipated to have lucrative growth opportunities in the future with the rising demand for antiviral combination therapies in the global market. Below mentioned is the list of few companies engaged in the antiviral combination therapies market.

The report also includes the profiles of key players in antiviral combination therapies market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.


The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antiviral Combination Therapies Market - By Drug Combination
1.3.2 Antiviral Combination Therapies Market - By Type
1.3.3 Antiviral Combination Therapies Market - By Indication
1.3.4 Antiviral Combination Therapies Market - By Route of Administration
1.3.5 Antiviral Combination Therapies Market - By Distribution Channel
1.3.6 Antiviral Combination Therapies Market - By Region
1.3.6.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTIVIRAL COMBINATION THERAPIES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIVIRAL COMBINATION THERAPIES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTIVIRAL COMBINATION THERAPIES MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIVIRAL COMBINATION THERAPIES - GLOBAL MARKET OVERVIEW
6.2. ANTIVIRAL COMBINATION THERAPIES - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIVIRAL COMBINATION THERAPIES MARKET - REVENUE AND FORECASTS TO 2027 - DRUG COMBINATION
7.1. OVERVIEW
7.2. DRUG COMBINATION MARKET FORECASTS AND ANALYSIS
7.3. NRTI/NNRTI
7.3.1. Overview
7.3.2. NRTI/NNRTI Market Forecast and Analysis
7.4. INTEGRASE INHIBITOR/NRTI
7.4.1. Overview
7.4.2. Integrase Inhibitor/NRTI Market Forecast and Analysis
7.5. NRTI
7.5.1. Overview
7.5.2. NRTI Market Forecast and Analysis
7.6. NRTI/PROTEASE INHIBITOR
7.6.1. Overview
7.6.2. NRTI/Protease Inhibitor Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ANTIVIRAL COMBINATION THERAPIES MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
8.1. OVERVIEW
8.2. TYPE MARKET FORECASTS AND ANALYSIS
8.3. BRANDED
8.3.1. Overview
8.3.2. Branded Market Forecast and Analysis
8.4. GENERIC
8.4.1. Overview
8.4.2. Generic Market Forecast and Analysis
9. ANTIVIRAL COMBINATION THERAPIES MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
9.1. OVERVIEW
9.2. INDICATION MARKET FORECASTS AND ANALYSIS
9.3. HIV
9.3.1. Overview
9.3.2. HIV Market Forecast and Analysis
9.4. HEPATITIS
9.4.1. Overview
9.4.2. Hepatitis Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. ANTIVIRAL COMBINATION THERAPIES MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
10.1. OVERVIEW
10.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
10.3. ORAL
10.3.1. Overview
10.3.2. Oral Market Forecast and Analysis
10.4. INTRAVENOUS
10.4.1. Overview
10.4.2. Intravenous Market Forecast and Analysis
11. ANTIVIRAL COMBINATION THERAPIES MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
11.1. OVERVIEW
11.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
11.3. HOSPITAL PHARMACIES
11.3.1. Overview
11.3.2. Hospital Pharmacies Market Forecast and Analysis
11.4. RETAIL PHARMACIES
11.4.1. Overview
11.4.2. Retail Pharmacies Market Forecast and Analysis
11.5. OTHERS
11.5.1. Overview
11.5.2. Others Market Forecast and Analysis
12. ANTIVIRAL COMBINATION THERAPIES MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1 North America Antiviral Combination Therapies Market Overview
12.1.2 North America Antiviral Combination Therapies Market Forecasts and Analysis
12.1.3 North America Antiviral Combination Therapies Market Forecasts and Analysis - By Drug Combination
12.1.4 North America Antiviral Combination Therapies Market Forecasts and Analysis - By Type
12.1.5 North America Antiviral Combination Therapies Market Forecasts and Analysis - By Indication
12.1.6 North America Antiviral Combination Therapies Market Forecasts and Analysis - By Route of Administration
12.1.7 North America Antiviral Combination Therapies Market Forecasts and Analysis - By Distribution Channel
12.1.8 North America Antiviral Combination Therapies Market Forecasts and Analysis - By Countries
12.1.8.1 United States Antiviral Combination Therapies Market
12.1.8.1.1 United States Antiviral Combination Therapies Market by Drug Combination
12.1.8.1.2 United States Antiviral Combination Therapies Market by Type
12.1.8.1.3 United States Antiviral Combination Therapies Market by Indication
12.1.8.1.4 United States Antiviral Combination Therapies Market by Route of Administration
12.1.8.1.5 United States Antiviral Combination Therapies Market by Distribution Channel
12.1.8.2 Canada Antiviral Combination Therapies Market
12.1.8.2.1 Canada Antiviral Combination Therapies Market by Drug Combination
12.1.8.2.2 Canada Antiviral Combination Therapies Market by Type
12.1.8.2.3 Canada Antiviral Combination Therapies Market by Indication
12.1.8.2.4 Canada Antiviral Combination Therapies Market by Route of Administration
12.1.8.2.5 Canada Antiviral Combination Therapies Market by Distribution Channel
12.1.8.3 Mexico Antiviral Combination Therapies Market
12.1.8.3.1 Mexico Antiviral Combination Therapies Market by Drug Combination
12.1.8.3.2 Mexico Antiviral Combination Therapies Market by Type
12.1.8.3.3 Mexico Antiviral Combination Therapies Market by Indication
12.1.8.3.4 Mexico Antiviral Combination Therapies Market by Route of Administration
12.1.8.3.5 Mexico Antiviral Combination Therapies Market by Distribution Channel
12.2. EUROPE
12.2.1 Europe Antiviral Combination Therapies Market Overview
12.2.2 Europe Antiviral Combination Therapies Market Forecasts and Analysis
12.2.3 Europe Antiviral Combination Therapies Market Forecasts and Analysis - By Drug Combination
12.2.4 Europe Antiviral Combination Therapies Market Forecasts and Analysis - By Type
12.2.5 Europe Antiviral Combination Therapies Market Forecasts and Analysis - By Indication
12.2.6 Europe Antiviral Combination Therapies Market Forecasts and Analysis - By Route of Administration
12.2.7 Europe Antiviral Combination Therapies Market Forecasts and Analysis - By Distribution Channel
12.2.8 Europe Antiviral Combination Therapies Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Antiviral Combination Therapies Market
12.2.8.1.1 Germany Antiviral Combination Therapies Market by Drug Combination
12.2.8.1.2 Germany Antiviral Combination Therapies Market by Type
12.2.8.1.3 Germany Antiviral Combination Therapies Market by Indication
12.2.8.1.4 Germany Antiviral Combination Therapies Market by Route of Administration
12.2.8.1.5 Germany Antiviral Combination Therapies Market by Distribution Channel
12.2.8.2 France Antiviral Combination Therapies Market
12.2.8.2.1 France Antiviral Combination Therapies Market by Drug Combination
12.2.8.2.2 France Antiviral Combination Therapies Market by Type
12.2.8.2.3 France Antiviral Combination Therapies Market by Indication
12.2.8.2.4 France Antiviral Combination Therapies Market by Route of Administration
12.2.8.2.5 France Antiviral Combination Therapies Market by Distribution Channel
12.2.8.3 Italy Antiviral Combination Therapies Market
12.2.8.3.1 Italy Antiviral Combination Therapies Market by Drug Combination
12.2.8.3.2 Italy Antiviral Combination Therapies Market by Type
12.2.8.3.3 Italy Antiviral Combination Therapies Market by Indication
12.2.8.3.4 Italy Antiviral Combination Therapies Market by Route of Administration
12.2.8.3.5 Italy Antiviral Combination Therapies Market by Distribution Channel
12.2.8.4 Spain Antiviral Combination Therapies Market
12.2.8.4.1 Spain Antiviral Combination Therapies Market by Drug Combination
12.2.8.4.2 Spain Antiviral Combination Therapies Market by Type
12.2.8.4.3 Spain Antiviral Combination Therapies Market by Indication
12.2.8.4.4 Spain Antiviral Combination Therapies Market by Route of Administration
12.2.8.4.5 Spain Antiviral Combination Therapies Market by Distribution Channel
12.2.8.5 United Kingdom Antiviral Combination Therapies Market
12.2.8.5.1 United Kingdom Antiviral Combination Therapies Market by Drug Combination
12.2.8.5.2 United Kingdom Antiviral Combination Therapies Market by Type
12.2.8.5.3 United Kingdom Antiviral Combination Therapies Market by Indication
12.2.8.5.4 United Kingdom Antiviral Combination Therapies Market by Route of Administration
12.2.8.5.5 United Kingdom Antiviral Combination Therapies Market by Distribution Channel
12.2.8.6 Rest of Europe Antiviral Combination Therapies Market
12.2.8.6.1 Rest of Europe Antiviral Combination Therapies Market by Drug Combination
12.2.8.6.2 Rest of Europe Antiviral Combination Therapies Market by Type
12.2.8.6.3 Rest of Europe Antiviral Combination Therapies Market by Indication
12.2.8.6.4 Rest of Europe Antiviral Combination Therapies Market by Route of Administration
12.2.8.6.5 Rest of Europe Antiviral Combination Therapies Market by Distribution Channel
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Antiviral Combination Therapies Market Overview
12.3.2 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis
12.3.3 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis - By Drug Combination
12.3.4 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis - By Type
12.3.5 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis - By Indication
12.3.6 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis - By Route of Administration
12.3.7 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis - By Distribution Channel
12.3.8 Asia-Pacific Antiviral Combination Therapies Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Antiviral Combination Therapies Market
12.3.8.1.1 Australia Antiviral Combination Therapies Market by Drug Combination
12.3.8.1.2 Australia Antiviral Combination Therapies Market by Type
12.3.8.1.3 Australia Antiviral Combination Therapies Market by Indication
12.3.8.1.4 Australia Antiviral Combination Therapies Market by Route of Administration
12.3.8.1.5 Australia Antiviral Combination Therapies Market by Distribution Channel
12.3.8.2 China Antiviral Combination Therapies Market
12.3.8.2.1 China Antiviral Combination Therapies Market by Drug Combination
12.3.8.2.2 China Antiviral Combination Therapies Market by Type
12.3.8.2.3 China Antiviral Combination Therapies Market by Indication
12.3.8.2.4 China Antiviral Combination Therapies Market by Route of Administration
12.3.8.2.5 China Antiviral Combination Therapies Market by Distribution Channel
12.3.8.3 India Antiviral Combination Therapies Market
12.3.8.3.1 India Antiviral Combination Therapies Market by Drug Combination
12.3.8.3.2 India Antiviral Combination Therapies Market by Type
12.3.8.3.3 India Antiviral Combination Therapies Market by Indication
12.3.8.3.4 India Antiviral Combination Therapies Market by Route of Administration
12.3.8.3.5 India Antiviral Combination Therapies Market by Distribution Channel
12.3.8.4 Japan Antiviral Combination Therapies Market
12.3.8.4.1 Japan Antiviral Combination Therapies Market by Drug Combination
12.3.8.4.2 Japan Antiviral Combination Therapies Market by Type
12.3.8.4.3 Japan Antiviral Combination Therapies Market by Indication
12.3.8.4.4 Japan Antiviral Combination Therapies Market by Route of Administration
12.3.8.4.5 Japan Antiviral Combination Therapies Market by Distribution Channel
12.3.8.5 South Korea Antiviral Combination Therapies Market
12.3.8.5.1 South Korea Antiviral Combination Therapies Market by Drug Combination
12.3.8.5.2 South Korea Antiviral Combination Therapies Market by Type
12.3.8.5.3 South Korea Antiviral Combination Therapies Market by Indication
12.3.8.5.4 South Korea Antiviral Combination Therapies Market by Route of Administration
12.3.8.5.5 South Korea Antiviral Combination Therapies Market by Distribution Channel
12.3.8.6 Rest of Asia-Pacific Antiviral Combination Therapies Market
12.3.8.6.1 Rest of Asia-Pacific Antiviral Combination Therapies Market by Drug Combination
12.3.8.6.2 Rest of Asia-Pacific Antiviral Combination Therapies Market by Type
12.3.8.6.3 Rest of Asia-Pacific Antiviral Combination Therapies Market by Indication
12.3.8.6.4 Rest of Asia-Pacific Antiviral Combination Therapies Market by Route of Administration
12.3.8.6.5 Rest of Asia-Pacific Antiviral Combination Therapies Market by Distribution Channel
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Antiviral Combination Therapies Market Overview
12.4.2 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis
12.4.3 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis - By Drug Combination
12.4.4 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis - By Type
12.4.5 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis - By Indication
12.4.6 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis - By Route of Administration
12.4.7 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis - By Distribution Channel
12.4.8 Middle East and Africa Antiviral Combination Therapies Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Antiviral Combination Therapies Market
12.4.8.1.1 South Africa Antiviral Combination Therapies Market by Drug Combination
12.4.8.1.2 South Africa Antiviral Combination Therapies Market by Type
12.4.8.1.3 South Africa Antiviral Combination Therapies Market by Indication
12.4.8.1.4 South Africa Antiviral Combination Therapies Market by Route of Administration
12.4.8.1.5 South Africa Antiviral Combination Therapies Market by Distribution Channel
12.4.8.2 Saudi Arabia Antiviral Combination Therapies Market
12.4.8.2.1 Saudi Arabia Antiviral Combination Therapies Market by Drug Combination
12.4.8.2.2 Saudi Arabia Antiviral Combination Therapies Market by Type
12.4.8.2.3 Saudi Arabia Antiviral Combination Therapies Market by Indication
12.4.8.2.4 Saudi Arabia Antiviral Combination Therapies Market by Route of Administration
12.4.8.2.5 Saudi Arabia Antiviral Combination Therapies Market by Distribution Channel
12.4.8.3 U.A.E Antiviral Combination Therapies Market
12.4.8.3.1 U.A.E Antiviral Combination Therapies Market by Drug Combination
12.4.8.3.2 U.A.E Antiviral Combination Therapies Market by Type
12.4.8.3.3 U.A.E Antiviral Combination Therapies Market by Indication
12.4.8.3.4 U.A.E Antiviral Combination Therapies Market by Route of Administration
12.4.8.3.5 U.A.E Antiviral Combination Therapies Market by Distribution Channel
12.4.8.4 Rest of Middle East and Africa Antiviral Combination Therapies Market
12.4.8.4.1 Rest of Middle East and Africa Antiviral Combination Therapies Market by Drug Combination
12.4.8.4.2 Rest of Middle East and Africa Antiviral Combination Therapies Market by Type
12.4.8.4.3 Rest of Middle East and Africa Antiviral Combination Therapies Market by Indication
12.4.8.4.4 Rest of Middle East and Africa Antiviral Combination Therapies Market by Route of Administration
12.4.8.4.5 Rest of Middle East and Africa Antiviral Combination Therapies Market by Distribution Channel
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Antiviral Combination Therapies Market Overview
12.5.2 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis
12.5.3 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis - By Drug Combination
12.5.4 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis - By Type
12.5.5 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis - By Indication
12.5.6 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis - By Route of Administration
12.5.7 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis - By Distribution Channel
12.5.8 South and Central America Antiviral Combination Therapies Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Antiviral Combination Therapies Market
12.5.8.1.1 Brazil Antiviral Combination Therapies Market by Drug Combination
12.5.8.1.2 Brazil Antiviral Combination Therapies Market by Type
12.5.8.1.3 Brazil Antiviral Combination Therapies Market by Indication
12.5.8.1.4 Brazil Antiviral Combination Therapies Market by Route of Administration
12.5.8.1.5 Brazil Antiviral Combination Therapies Market by Distribution Channel
12.5.8.2 Argentina Antiviral Combination Therapies Market
12.5.8.2.1 Argentina Antiviral Combination Therapies Market by Drug Combination
12.5.8.2.2 Argentina Antiviral Combination Therapies Market by Type
12.5.8.2.3 Argentina Antiviral Combination Therapies Market by Indication
12.5.8.2.4 Argentina Antiviral Combination Therapies Market by Route of Administration
12.5.8.2.5 Argentina Antiviral Combination Therapies Market by Distribution Channel
12.5.8.3 Rest of South and Central America Antiviral Combination Therapies Market
12.5.8.3.1 Rest of South and Central America Antiviral Combination Therapies Market by Drug Combination
12.5.8.3.2 Rest of South and Central America Antiviral Combination Therapies Market by Type
12.5.8.3.3 Rest of South and Central America Antiviral Combination Therapies Market by Indication
12.5.8.3.4 Rest of South and Central America Antiviral Combination Therapies Market by Route of Administration
12.5.8.3.5 Rest of South and Central America Antiviral Combination Therapies Market by Distribution Channel
13. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET
13.1 North America
13.2 Europe
13.3 Asia-Pacific
13.4 Rest of the World
14. INDUSTRY LANDSCAPE
14.1. MERGERS AND ACQUISITIONS
14.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
14.3. NEW PRODUCT LAUNCHES
14.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
15. ANTIVIRAL COMBINATION THERAPIES MARKET, KEY COMPANY PROFILES
15.1. CELLTRION, INC.
15.1.1. Key Facts
15.1.2. Business Description
15.1.3. Products and Services
15.1.4. Financial Overview
15.1.5. SWOT Analysis
15.1.6. Key Developments
15.2. GLAXOSMITHKLINE PLC
15.2.1. Key Facts
15.2.2. Business Description
15.2.3. Products and Services
15.2.4. Financial Overview
15.2.5. SWOT Analysis
15.2.6. Key Developments
15.3. GILEAD SCIENCES, INC.
15.3.1. Key Facts
15.3.2. Business Description
15.3.3. Products and Services
15.3.4. Financial Overview
15.3.5. SWOT Analysis
15.3.6. Key Developments
15.4
The List of Companies

1. Celltrion, Inc.
2. GlaxoSmithKline plc
3. Gilead Sciences, Inc.
4. AbbVie, Inc.
5. Bristol-Myers Squibb Company
6. Janssen Global Services
7. Cipla, Inc.
8. Mylan N.V.
9. Merck & Co., Inc.
10. F. Hoffmann-La Roche Ltd.
TIPRE00015971
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking